AXL-specific single domain antibodies show diagnostic potential and anti-tumor activity in Acute Myeloid Leukemia
Niels Vandewalle, Hatice Satilmis, Emma Verheye, Rong Fan, Yanmeng Wang, Timo W.M. De Groof, Jessica Bridoux, Tessa Kerre, Nathan De Beule, Ann De Becker, Elke De Bruyne, Eline Menu, Karin Vanderkerken, Karine Breckpot, Nick Devoogdt, Kim De Veirman
Abstract
Because of their diagnostic potential, sdAbs could be used to screen patients eligible for AXL-targeted therapy and to follow-up AXL expression during treatment and disease progression. When fused to an Fc-domain, sdAbs acquire additional therapeutic properties that can lead to a multidrug approach for the treatment of AXL-positive cancer patients.
Topics & Concepts
Myeloid leukemiaAntibodyCancer researchMyeloidLeukemiaMedicineImmunologyPhagocytosis and Immune RegulationChronic Lymphocytic Leukemia ResearchAcute Myeloid Leukemia Research